Y tal vez ser capaz de pasar de tener miedo a tener esperanza
Altimmunes GLP-1 agonist in the clinic Some biotechs think that by broadening the therapeutic scope of GLP-1 agonists, cardiovascular diseases can be addressed
However, the researchers warned that despite the limited benefits, drugs like Ozempic and Mounjaro also carry increased risks for 19 adverse health outcomes, primarily affecting the gastrointestinal system
For continuation versus noncontinuation, the weighted prevalence ratios were 1.29 (95 percent confidence interval, 0.82 to 2.06), 1.08 (95 percent confidence interval, 0.84 to 1.40), and 1.21 (95 percent confidence interval, 0.83 to 1.82) for small for gestational age, large for gestational age, and MCM, respectively."Accumulated evidence provides some reassurance about risk for malformations after inadvertent exposure in women who become pregnant while using GLP-1 RAs," the authors write.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter
